NCT00901602 Lebanese Interhospital Pneumococcal Surveillance Program
| NCT ID | NCT00901602 |
| Status | Recruiting |
| Phase | — |
| Sponsor | American University of Beirut Medical Center |
| Condition | Pneumonia |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2005-10 |
| Primary Completion | 2030-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2005-10 with a primary completion date of 2030-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection. There are many types of these bacteria defined by the type of sugar coat that they have. These are classified as serotypes. There are common serotypes that cause severe disease and are preventable by vaccination of children. Other less common types are more difficult to prevent. The investigators aim to determine the serotypes that cause invasive pneumococcal disease in Lebanon and to study their sensitivity to different antibiotics. The investigators will collect bacterial isolates from different hospitals in Lebanon isolated from the blood or spinal fluid of patients with invasive pneumococcal disease. This information will help the investigators determine the usefulness of available pneumococcal vaccines in preventing these infections. The data will be distributed to all primary care physicians treating children in Lebanon and will be shared with the Ministry of Health.
Eligibility Criteria
Inclusion Criteria: * Samples included in the study are those that are: * culture proven * invasive pneumococcal infections * in patients of all ages admitted to different hospitals all over Lebanon * Acceptable samples include: * positive isolates from blood * cerebrospinal fluid * other normally sterile body sites such as empyema fluid, abscesses, joint fluid, middle ear fluid obtained by tympanocentesis in the operating room, and lung needle aspiration Exclusion Criteria: * non S. pneumoniae isolates
Contact & Investigator
Ghassan S Dbaibo, M.D.
PRINCIPAL INVESTIGATOR
American University of Beirut Medical Center
Frequently Asked Questions
Who can join the NCT00901602 clinical trial?
This trial is open to participants of all sexes, aged 1 Day or older, studying Pneumonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00901602 currently recruiting?
Yes, NCT00901602 is actively recruiting participants. Contact the research team at gdbaibo@aub.edu.lb for enrollment information.
Where is the NCT00901602 trial being conducted?
This trial is being conducted at Beirut, Lebanon.
Who is sponsoring the NCT00901602 clinical trial?
NCT00901602 is sponsored by American University of Beirut Medical Center. The principal investigator is Ghassan S Dbaibo, M.D. at American University of Beirut Medical Center. The trial plans to enroll 700 participants.